Weizmann scientist's invention moves forward: Cancer diagnosis technique gets FDA clearance

September 22, 2003

Rehovot, Israel--September 23, 2003-- Thanks to a diagnostic imaging technique that should soon be finding its way to medical establishments, many patients could be spared the pain and risk of biopsies. The technique, called 3TP, has recently received FDA clearance for use in the detection of breast and prostate cancer, and is slated for distribution as early as next year. It will enable doctors to distinguish between malignant tumors and benign lumps by scanning instead of cutting.

3TP (Three Time Point) makes use of existing MRI scanners, and a safe contrast agent that is injected into the patient. The suspected tumor site is scanned by MRI repeatedly over a period of several minutes. The software developed for the method analyzes three of the MRI images, one before and two after the injection (hence the name 3TP), and then creates a colored likeness of the breast or prostate area based on the resulting data. A preponderance of red in the picture indicates malignancy, while mainly blue and green are signs of a benign growth.

The procedure, developed by Prof. Hadassa Degani and her research group at the Weizmann Institute of Science Biological Regulation Dept., arose from her research on the development of cancerous tumors. Typically, malignancies, which need a steady supply of oxygen and nutrients in order to grow, contain many small, new blood vessels. Blood flow in and out of the area of the tumor is usually accelerated. Tumor cells are distributed unevenly, with areas of densely packed cells that have tighter between-cell spaces than normal.

In order to obtain the 3TP image, the contrast agent, which enhances the MRI images, is injected into the bloodstream, and the flow of the agent into the area being scanned is traced. The agent, which quickly passes through the blood, will enter and clear out of a cancerous tumor faster, and contrast agent escaping vessel walls (new blood vessels tend to leak) will be highlighted, along with the spaces between cells. By making calculations based on comparisons between the images, the software can assign a color to each tiny pixel making up the graphic image.

Several hospitals in the U.S. have participated in the clinical trials, testing hundreds of patients who were slated to undergo biopsies. The 3TP scans were sent to Degani's lab in Israel for analysis, and her diagnoses were later compared with the results of the biopsies. Tests were conducted in such a way that Degani knew nothing about the patient's medical history, thus her results were based solely on the 3TP image. Doctors, as well, did not see the 3TP results until they had reached a diagnosis through biopsy. In impressive trial results, solid growths larger than five millimeters (1/5 inch) were diagnosed correctly using 3TP nearly 100% of the time. For all trials, including patients with DCIS (a non-invasive, non-lump-forming cancer in the milk ducts), the accuracy rate was close to 90%.

While others have come up with various methods of diagnosing cancer using MRI technology, Degani emphasizes that the 3TP technique is the only one that provides an accurate, standardized system that any clinician can easily use. The speed with which results can be obtained and the prevention of unnecessary biopsies will make it cost-effective as well. The procedure is likely to be used in the future to diagnose a variety of cancers and, while it is moving from the trial stages to clinical use on breast and prostate, research is starting on the lungs. In addition, more research will be done on using 3TP scanning to track the response of tumors to anti-cancer therapies.
-end-
The method will be distributed by a U.S. company called 3TP LLC. In operation a little over a year, it was founded to market the 3TP technology, to which it received worldwide rights through Yeda, the commercial arm of the Weizmann Institute. Because 3TP is non-invasive, and is based on existing MRI technology, the FDA clearing process was shorter than expected. Now the company, presently engaged in beta-testing of its product in six American medical institutions, is seeking clearance in Canada and Europe. 3TP LLC can be contacted at (1) 631-702-2400; JRM3TP@hamptons.com.

Prof. Hadassa Degani's research is supported by Sir David Alliance, CBE, UK; M.D. Moross Institute for Cancer Research; Mr. and Mrs. Lon Morton, Calabasas, CA; Mrs. Jackie Gee, Ms. Livia Meyer and Mr. Harry Woolf, UK; Ms. Lynne Mochon and Ms. Edith Degani, NY, USA; The Washington Square Health Foundation; Willner Family Center for Vascular Biology; and The Estate of Mrs. Ilse Katz, Switzerland.

Prof. Degani is the incumbent of the Fred and Andrea Fallek Professorial Chair in Breast Cancer Research.

The Weizmann Institute of Science, in Rehovot, Israel, is one of the world's foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians, and engineers pursue basic research in the quest for knowledge and the enhancement of humanity. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities at Weizmann.

American Committee for the Weizmann Institute of Science

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.